180

EUIPO EUIPO 2022 Trademark registered

Protect this trademark from copycats!

With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.

The Union trademark 180 was filed as Figurative mark on 08/04/2022 at the European Union Intellectual Property Office.
It was registered as a trademark on 12/16/2022. The current status of the mark is "Trademark registered".

Logodesign (Wiener Klassifikation)

#Bubbles, frothy masses, speech bubbles

Trademark Details Last update: February 14, 2023

Trademark form Figurative mark
File reference 018742014
Application date August 4, 2022
Publication date September 8, 2022
Entry date December 16, 2022
Expiration date August 4, 2032

Trademark owner

Building 4, Suite 200 3000 El Camino Real
94306 Palo Alto
US

Trademark representatives

Widenmayerstr. 10 80538 München DE

goods and services

5 Analgesic preparations; pharmaceutical preparations for the treatment of inflammatory diseases; pharmaceutical preparations for the treatment of inflammation; pharmaceutical preparations for the treatment of dupuytren's disease; pharmaceutical preparations for the treatment of frozen shoulder; pharmaceutical preparations for the treatment of post-operative delirium; pharmaceutical preparations for the treatment of post-operative cognitive deficit; pharmaceutical preparations for the treatment of post-operative cognitive decline; pharmaceutical preparations for the treatment of non-alcoholic steatohepatitis; pharmaceutical preparations for the treatment of fibrosis; pharmaceutical preparations for the treatment of liver fibrosis; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of ulcerative colitis; pharmaceutical preparations for the treatment of anxiety; pharmaceutical preparations for the treatment of type 1 diabetes; pharmaceutical preparations for the treatment of type 2 diabetes; pharmaceutical preparations for inhibition of tumor necrosis factor (tnf); pharmaceutical preparations for interacting with nicotine receptors; pharmaceutical preparations for synthetically simulating non-psychoactive effects of cannabidiol (cbd); pharmaceutical preparations for liver regeneration; pharmaceutical preparations for regenerative therapy; pharmaceutical preparations for acting as an alpha-7nachr agonist
42 Development of pharmaceutical preparations and medicines; pharmaceutical drug development services; pharmaceutical product evaluation; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development in the pharmaceutical and biotechnology fields; scientific research for medical purposes in the field of inflammatory diseases; scientific research for medical purposes in the field of treatment of inflammation; scientific research for medical purposes in the field of dupuytren's disease; scientific research for medical purposes in the field of frozen shoulder; scientific research for medical purposes in the field of post-operative delirium, post-operative cognitive deficit, and post-operative cognitive decline; scientific research for medical purposes in the field of non-alcoholic steatohepatitis; scientific research for medical purposes in the field of fibrosis; scientific research for medical purposes in the field of liver fibrosis; scientific research for medical purposes in the field of arthritis; scientific research for medical purposes in the field of pain treatment; scientific research for medical purposes in the field of ulcerative colitis; scientific research for medical purposes in the field of treatment of anxiety; scientific research for medical purposes in the field of inhibition of tumor necrosis factor (tnf) and anti-tnf pharmaceuticals; scientific research for medical purposes in the field of interactions with nicotine receptors; scientific research for medical purposes in the field of synthetic simulation of non-psychoactive effects of cannabidiol (cbd); scientific research for medical purposes in the field of synthetic cannabidiol (cbd) analogs; scientific research for medical purposes in the field of type 1 diabetes; scientific research for medical purposes in the field of type 2 diabetes; scientific research for medical purposes in the field of liver regeneration; scientific research for medical purposes in the field of regenerative therapy; scientific research for medical purposes in the field of alpha-7nachr agonists

ID: 11018742014